Injections of a novel protein reduced artery blockage by enhancing lymphatic vascular function in mice

Study Highlights:

  • Mice that received injections of a protein called VEGF-C experienced about a 30% reduction in artery blockage compared to untreated mice.
  • The VEGF-C injections improved lymphatic transport, limited plaque formation and stabilized plaque even after mice were switched to a high-fat diet.

Embargoed until 9:30 a.m. CT/10:30 a.m. ET, Tuesday, May 14, 2019

(NewMediaWire) - May 14, 2019 - BOSTON - Injections of a protein associated with healthy lymphatic vessel function reduced artery blockage known as atherosclerosis in mice. This finding could one day provide a new way to prevent and treat heart disease and stroke through targeting the lymphatic system, according to the preliminary research presented at the American Heart Association’s Vascular Discovery Scientific Sessions 2019, a premier global exchange of the latest advances in new and emerging scientific research in arteriosclerosis, thrombosis, vascular biology, peripheral vascular disease, vascular surgery and functional genomics.

Researchers set out to determine how early exposure to the protein would affect plaque build-up that can lead to heart disease, and if the protein could reduce or even stave off blockages. They found mice that received injections of a protein called VEGF-C 152S experienced about a 30% reduction in plaque in the arteries compared to mice that did not receive the protein.

Young mice, genetically modified to lack LDL receptors, received injections three times per week for four weeks while on a regular diet. Then, the shots were discontinued while the mice fed a high-fat diet for eight weeks to induce atherosclerosis before resuming a regular diet for another four weeks. The VEGF-C 152S injections managed to cut down plaque build-up despite eight weeks on a high-fat diet. Additionally, plaque in the injected mice was more stable, a benefit that could potentially reduce strokes from plaque breaking off and traveling to the brain.

The protein, VEGF-C 152S, is associated with reduced inflammation and improved lymphatic blood vessel function. It is also critical to the development of new lymphatic vessels.

Researchers said the lymphatic system, a network of tissues and organs typically associated with clearing the body of waste, is understudied in atherosclerosis. However, the connection between the lymphatic system and cholesterol accumulation within the artery wall may yield new insights.

“Our findings show that atherosclerosis can be curbed, perhaps even prevented, if we target the lymphatic system early on,” said Andreea Milasan, M.Sc., lead author of the study and a Ph.D. candidate in the laboratory of Dr. Catherine Martel at the Montreal Heart Institute in Montreal, Quebec, Canada. “The movement of lymph through the body affects the clearance of cholesterol and inflammatory components that are stuck in the artery wall, and the lymphatic system is now emerging as a potential contributor to understanding heart health and the development of cardiovascular disease.”

Milasan said researchers need to zero in on the exact biological mechanisms behind how targeting lymphatic function early enough in patients at risk of developing coronary heart disease could protect blood vessel health.

Co-authors are: Ali Smaani, B.Sc., and Catherine Martel, Ph.D. Author disclosures are on the abstract.

Funding for the study was provided by Montreal Heart Institute Foundation, the Banting Research Foundation, the Fonds de Recherche du Quebec – Santé, the Foundation Jacques-de-Champlain/Heart and Stroke Foundation, the Canadian Institutes of Health Research and the Fonds de Recherche du Quebec – Santé early career investigator and doctoral training grants.

Note: Scientific presentation is 11:15 a.m. ET, Tuesday, May 14, 2019.

Additional Resources:

###

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.

About the American Heart Association

The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.

For Media Inquiries and AHA Expert Perspective: 214-706-1173

Cathy Lewis – 214-706-1324; cathy.lewis@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and strokeassociation.org